Presenter: Carl Amilon (AstraZeneca)

Date: June 10, 2020

Description:

This webinar will give an overview of how incorporating quantitative PK/PD aspects of an oligonucleotide will help you designing more informative experiments and help in translating to a human. We have all struggled with questions around the expectations of a study outcome and how to optimize the design. The talk will give you some simple to use tools and discuss common pitfalls to help you in design and interpretation of studies.

• ADME: Assessing Pharmacokinetic-Pharmacodynamic Parameters of Oligonucleotides.
  Jansson-Löfmark R, Ahlström C, Gennemark P. Methods
  Mol Biol. 2019;2036:317-339.
• Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers.
  Danhof M, Alvan G, Dahl SG, Kuhlmann J, Paintaud G.
  Pharm Res. 2005 Sep;22(9):1432-7.
• FDA Guidance on NASH: Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease.
  Bianchi S, Bigazzi R, Campese VM.
  Kidney Int. 2006 Dec;70(12):2116-23.
• Drug metabolism and pharmacokinetic strategies for oligonucleotide- and mRNA-based drug development.
  Andersson S, Antonsson M, Elebring M, Jansson-Löfmark R, Weidolf L.
  Drug Discov Today. 2018 Oct;23(10):1733-1745.
• Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100.
  Yu RZ, Kim TW, Hong A, Watanabe TA, Gaus HJ, Geary RS.
  Drug Metab Dispos. 2007 Mar;35(3):460-8.
• Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2′-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species.
  Geary RS, Yu RZ, Watanabe T, Henry SP, Hardee GE, Chappell A, Matson J, Sasmor H, Cummins L, Levin AA.
  Drug Metab Dispos. 2003 Nov;31(11):1419-28.

Carl Amilon was awarded his PhD in Pharmacokinetics and Pharmacodynamics from the Department of Pharmacology at the University of Gothenburg in 2013. His research focused on optimizing dosing regimen of a anti-infective drug using a PK/PD modelling. Carl joined Quantitative Clinical Pharmacology at AstraZeneca in 2013, and supported several projects in both early and late clinical development stages with a special interest in pediatric drug development. Since 2017, Carl is working as a DMPK project lead with focus on early development of drug candidates, leading work on translating preclinical data into human for all drug modalities in the AstraZeneca portfolio.

0

0